-

Angry@Arthritis Founder and Osteoarthritis Patient Steve O’Keeffe Applauds ARPA-H Moonshot to Find a Cure as He Works to Eliminate Joint Replacements

It is personal for serial tech entrepreneur O’Keeffe, who founded the non-profit Angry@Arthritis to partner with research centers, patient advocates and elected officials to push for new treatments that could make joint replacement obsolete for millions of people

original Steve O'Keeffe, Founder, Angry@Arthritis

Steve O'Keeffe, Founder, Angry@Arthritis

ALEXANDRIA, Va.--(BUSINESS WIRE)--Osteoarthritis (OA) cripples 1 in 7 American adults. That’s more than 32 million people – including tech entrepreneur and non-profit Angry@Arthritis founder Steve O’Keeffe.

O’Keeffe commented on the announcement of the Advanced Research Projects Agency for Health’s (ARPA-H) new Novel Innovations for Tissue Regeneration in OsteoArthritis (NITRO) program – America’s moonshot to cure OA:

“Right now, the only FDA-approved treatment is to cut out and replace OA joints with synthetics that limit mobility and break down in 10-15 years. That’s unacceptable, and yet every year Americans get 2.5 million of these replacements because it’s our only option. We’re thrilled ARPA-H announced an OA moonshot to find out if we can help our joints heal themselves. This is huge news, and we’re going to do all we can to actively support this breakthrough program.”

Last month Angry@Arthritis and the Arthritis Foundation hosted Dr. Ross Uhrich, who heads NITRO at ARPA-H; U.S. Representatives Gerry Connolly (D-VA) and Debbie Dingell (D-MI); and, leading researchers at the 1st Annual OA Innovation Shark Tank on Capitol Hill to build an action plan to, as O’Keeffe says, “sling artificial joint replacements on the scrap heap.”

Steve O’Keeffe is available for interviews and on background. He can be reached at sokeeffe@300brand.com

About Angry@Arthritis

Angry@Arthritis is a new 501(c)(3) focused on attacking and eliminating osteoarthritis. We provide the patient’s guide to OA, raise money to fund new cures, and advocate for OA to the U.S. Congress. Stay in touch. Follow us on Facebook @AngryAtArthritis and on Twitter @AngryArthritis.

Contacts

Brenda Nashawaty, brenda@nashawaty.com, +1 617.688.3253

Industry:

Angry@Arthritis

Release Versions
English

Contacts

Brenda Nashawaty, brenda@nashawaty.com, +1 617.688.3253

More News From Angry@Arthritis

University of Basel Delivers First Biological Implants for Treatment of Cartilage Lesions and Osteoarthritis in Humans

BASEL, Switzerland--(BUSINESS WIRE)--The Department of Biomedicine at the University of Basel and the University Hospital Basel, today announced that it delivered the first surgical procedure to treat Osteoarthritis (OA) in humans. The procedure called Nasal Chondrocyte Tissue-Engineered Cartilage, or N-TEC, provides an innovative alternative to cure confined knee cartilage lesions as well as to address degenerative OA cases that have to date required knee joint replacements – prosthetics that...

Angry@Arthritis Launches 1st Global Osteoarthritis Clinical Trial Locator

ALEXANDRIA, Va.--(BUSINESS WIRE)--Angry@Arthritis, a nonprofit focused on attacking and eliminating Osteoarthritis (OA), today announced OA Fix ~Trials in the Mix, the first global OA developmental treatment analysis and clinical trial locator – https://www.angryarthritis.org/oa-fix-trials-in-the-mix/. Today, there is no cure or FDA-approved treatment for OA, which is the third most common disability in the U.S. It afflicts one in seven Americans – more than 32 million people. The disease levie...

Global Osteoarthritis Leaders Host OA Innovation Shark Tank Meeting at U.S. Congress to Showcase Promise of New Cures – Call for Increased Federal Funding and Transparency

WASHINGTON--(BUSINESS WIRE)--Marking National Arthritis Awareness Month in May, Angry@Arthritis and the Arthritis Foundation yesterday hosted the annual OA Innovation “Shark Tank” meeting on Capitol Hill to spotlight the promise of new treatments to cure osteoarthritis (OA). As researchers and industry demonstrate the success of OA treatments in clinical trials, the arthritis community is saluting innovation and asking Congress for increased OA funding to help cure this disease that afflicts on...
Back to Newsroom